Today's Nobel Prize for Physiology or Medicine relates to research on regulatory T cells nobelprize.org/prizes/medicin…
For readers interested in harnessing the biology of regulatory T cells to treat disease, here's a comprehensive review nature.com/articles/s4157…rdcu.be/eJHU8
Yesterday, the FDA approved the first drug for schizophrenia with a new mechanism of action for more than half a century. For more on this mechanism - targeting muscarinic acetylcholine receptors - here's a recent review tinyurl.com/mwpahd99rdcu.be/dVhpp
FDA approves first schizophrenia drug with a new mechanism of action since the 1950s tinyurl.com/34ceshw4
Karuna/Bristol Myers Squibb’s KarXT (Cobenfy), which acts on M1/M4 muscarinic acetylcholine receptors, expands the treatment landscape beyond dopamine-targeted drugs
The FDA has approved the first telomerase inhibitor, imetelstat, to treat myelodysplastic syndromes following an epic journey for the drug, which has been tested in more than 20 trials over the past 20 years in various cancers. Find out more here bit.ly/4ekijKL
For readers interested in mRNA vaccines for infectious diseases, including the discoveries that have been recognized in the #NobelPrize2023, here's a comprehensive review
bit.ly/3PMme7M
The 2021 Nobel Prize in Physiology or Medicine has been awarded to David Julius and Ardem Patapoutian for discoveries of receptors for temperature and touch, such as TRPV1 bit.ly/3uEK1eF Find out about drug discovery targeting TRP channels here rdcu.be/cyLfq
Targeting neutrophils for cancer therapy nature.com/articles/s4157…
Neutrophils are abundant in the tumour microenvironment and often correlate with poor prognosis. This new Review discusses neutrophil subtypes, mechanisms influencing tumour progression and therapeutic targets
Novel strategies to manage CAR-T cell toxicity tinyurl.com/ye3c94na
This new Review discusses management of safety issues for CAR-T cell therapies such as cytokine release syndrome, as well as druggable targets and cellular engineering strategies to develop safer CAR-T cells
The expanding role for small
molecules in immuno-oncology go.nature.com/3KkW9JT
A new review covering small molecules targeting cancer metabolism, cytokine/chemokine and innate immune pathways and T cell checkpoints that could be complementary to PD1/PDL1 inhibitors
For readers interested in CAR-T cell therapies in cancer immunotherapy, this Review in the May issue discusses management of toxicities and reviews druggable targets and cellular engineering strategies to develop safer CAR-T cells nature.com/articles/s4157…rdcu.be/em0rW
For readers interested in approaches to reset the immune system to treat autoimmune diseases, here's a comprehensive review nature.com/articles/s4157…rdcu.be/elE4L
For readers interested in cancer therapies, this Review in the October issue discusses how metabolic modulators and dietary nutrients can improve the anticancer immune response and overcome drug resistance mechanisms
rdcu.be/eLS8Anature.com/articles/s4157…
